Table of Contents:
  • The Australian imaging, biomarkers and lifestyle (aibl) flagship study of ageing
  • Methodology: key outcomes
  • Abeta and amyloid imaging
  • The progression of AD
  • Abeta and memory
  • Prediction of conversion from HC to MCI/AD
  • Impact of amyloid imaging in MCI patient selection for anti-amyloid therapeutic trials
  • Longitudinal PiB PET follow-up
  • Plasma Abeta 42 levels in the PiB-PET AIBL subset
  • Relation between Abeta oligomers in blood cellular elements, cognition and PiB SUVR
  • Plasma ApoE (total) levels: the AIBL study
  • Biomarker discovery
  • Abeta deposition